Table 4.
Five-year actuarial rates of local-regional control according to clinical and pathologic disease status by molecular subtype
| Factor | HR+/HER2- (n = 309) |
HR+/HER2+ (n = 51) |
HR-/HER2+ (n = 42) |
HR-/HER2- (n = 193) |
P-value |
|---|---|---|---|---|---|
| Clinical stage | |||||
| I/II (n = 473) | 98% | 95% | 86% | 91% | 0.004 |
| III (n = 120) | 92% | 100% | 89% | 84% | 0.25 |
| Number positive nodes* | |||||
| 0 to 3 (n = 517) | 98% | 95% | 89% | 91% | 0.007 |
| ≥ 4 (n = 75) | 93% | 100% | 67% | 56% | 0.001 |
| pCR | |||||
| No (n = 471) | 97% | 95% | 83% | 84% | < 001 |
| Yes (n = 124) | 96% | 100% | 92% | 99% | 0.62 |
| LVI | |||||
| No (n = 500) | 97% | 95% | 83% | 93% | 0.007 |
| Yes (n = 95) | 96% | 100% | 100% | 70% | 0.001 |
| Nuclear grade** | |||||
| 1 or 2 (n = 197) | 97% | 100% | 67% | 100% | 0.009 |
| 3 (n = 395) | 97% | 94% | 88% | 88% | 0.04 |
* In three patients the number of lymph nodes was unknown. ** In one patient, the nuclear grade was unknown. LRC, local-regional control; LVI, lymphovascular invasion; pCR, pathologic complete response